Skip to main content

Table 3 Baseline features of the patients

From: Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Studies Mean age (y) Males (%) HbA1c (%) Duration of DM (y) Bias risk assessment
  Exp/cont Exp/cont Exp/cont Exp/cont  
Bolli 2008 57.0/56.3 64.1/61.7 8.4/8.4 6.4/6.4 B
Garber 2006 54.8/54.0 50.7/49.9 8.7/8.65 4.8/4.75 B
Kim 2010 49.2/49.8 83.3/88.9 8.7/8.6 2.1/1.9 B
Rosenstock 2007 54.2/54.5 57.6/57.5 8.7/8.7 2.7/2.3 B
Rosenstock 2009 54.2/54.4 54.5/57.6 8.63/8.58 2.60/1.98 B
  1. Abbreviations: Exp experimental group (pioglitazone or rosiglitazone), Cont control group (vildagliptin), y year, DM diabetes mellitus